CNET1h
Eligible for Social Security Disability Insurance? Here's How to Apply
You can apply for Social Security Disability Insurance online, over the phone at 1-800-772-1213, or by stopping by a local ...
An appeals court has revived a challenge to President Biden’s Medicare drug price reduction program
A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...
Syndax Pharmaceuticals: Navigating Through A Pivotal Year
Is Syndax Pharmaceuticals, Inc. a buy after the recent stock decline? Analysts support, upcoming approvals, but expect a ...
Struggling with hair loss? This popular brand has a solution that stimulates new growth FAST: 'My hair is back to what it was in my mid-twenties'
SHOPPING: If you're done dealing with thinning hair, a receding hairline, and a lack of confidence, it's time to reverse the ...
Pharmabiz2d
Organon to buy Dermavant Sciences including its innovative dermatologic therapy, Vtama cream 1% to treat plaque psoriasis
Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...
Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary
As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...
Mena FN3d
Axial Spondyloarthritis Market - US To Have The Lion's Share Among The 7MM Delveinsight
In December 2021, Pfizer announced that the US FDA approved the supplemental New Drug Application (sNDA) for XELJANZ/XELJANZ XR (tofacitinib) for treating adults with active ankylosing spondylitis who ...
Zacks.com on MSN3d
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 7.4% in the last trading session to close at $53.17. The move was backed by solid volume with far more shares changing hands than in a normal session.
MT Newswires on MSN3d
Organon to Buy Roivant's Dermatology Unit For Up to $1.2 Billion
Organon (OGN) on Wednesday agreed to acquire Roivant Sciences' (ROIV) immuno-dermatology subsidiary, Dermavant, in a deal worth up to $1.2 billion. The healthcare company will pay $175 million upfront ...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...
FierceBiotech3d
FDA scraps adcomm for Applied's rare disease drug ahead of November decision
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...
Team publishes results from clinical trial evaluating cabozantinib in advanced neuroendocrine tumors
The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET ...